Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

Apr 28, 2022

SELL
$20.94 - $27.5 $270,733 - $355,547
-12,929 Closed
0 $0
Q4 2021

Jan 25, 2022

BUY
$16.79 - $27.09 $5,037 - $8,127
300 Added 2.38%
12,929 $302,000
Q3 2021

Oct 27, 2021

SELL
$15.78 - $24.77 $1,925 - $3,021
-122 Reduced 0.96%
12,629 $210,000
Q2 2021

Aug 10, 2021

BUY
$19.4 - $27.42 $247,369 - $349,632
12,751 New
12,751 $311,000
Q1 2021

Apr 28, 2021

SELL
$25.02 - $54.99 $138,785 - $305,029
-5,547 Closed
0 $0
Q4 2020

Feb 02, 2021

BUY
$41.04 - $56.79 $6,730 - $9,313
164 Added 3.05%
5,547 $297,000
Q3 2020

Oct 16, 2020

BUY
$36.42 - $57.0 $13,256 - $20,748
364 Added 7.25%
5,383 $222,000
Q2 2020

Jul 16, 2020

BUY
$39.26 - $52.73 $197,045 - $264,651
5,019 New
5,019 $243,000

Others Institutions Holding ACAD

About ACADIA PHARMACEUTICALS INC


  • Ticker ACAD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 161,843,008
  • Market Cap $2.39B
  • Description
  • ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...
More about ACAD
Track This Portfolio

Track Spearhead Capital Advisors, LLC Portfolio

Follow Spearhead Capital Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Spearhead Capital Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Spearhead Capital Advisors, LLC with notifications on news.